Wall Street analysts expect Tenax Therapeutics Inc (NASDAQ:TENX) to report earnings per share of ($0.42) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Tenax Therapeutics’ earnings. Tenax Therapeutics reported earnings of ($1.05) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 60%. The business is expected to announce its next earnings results on Wednesday, November 13th.
On average, analysts expect that Tenax Therapeutics will report full-year earnings of ($1.59) per share for the current year, with EPS estimates ranging from ($1.73) to ($1.44). For the next financial year, analysts expect that the business will report earnings of ($0.88) per share, with EPS estimates ranging from ($1.06) to ($0.71). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Tenax Therapeutics.
Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings data on Wednesday, August 14th. The specialty pharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.17.
Separately, ValuEngine raised shares of Tenax Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
Shares of TENX traded up $0.10 during trading hours on Monday, reaching $1.46. 18,074 shares of the company traded hands, compared to its average volume of 115,846. The stock has a market capitalization of $9.24 million, a P/E ratio of -0.16 and a beta of 1.35. The company has a quick ratio of 10.05, a current ratio of 10.05 and a debt-to-equity ratio of 0.01. Tenax Therapeutics has a 12-month low of $1.03 and a 12-month high of $6.39. The business has a fifty day moving average price of $1.26 and a 200-day moving average price of $1.47.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Susquehanna International Group LLP acquired a new position in Tenax Therapeutics during the second quarter valued at $30,000. Geode Capital Management LLC purchased a new position in shares of Tenax Therapeutics in the 4th quarter valued at $33,000. Finally, Renaissance Technologies LLC grew its position in shares of Tenax Therapeutics by 48.4% in the 2nd quarter. Renaissance Technologies LLC now owns 359,441 shares of the specialty pharmaceutical company’s stock valued at $496,000 after buying an additional 117,200 shares during the last quarter. Institutional investors own 16.83% of the company’s stock.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.
Featured Article: Put Option Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.